Improving cell health for single-cell proteomic analysis and immune monitoring

Presented By: Sean Mackay

Speaker Biography: Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy-to-use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

Webinar: Improving cell health for single-cell proteomic analysis and immune monitoring

Webinar Abstract: IsoPlexis’ single-cell proteomics is being applied widely to generate uniquely predictive insight into various biomarker studies, in a way that cannot be captured by traditional bulk metrics. Tissue based analysis remains a challenge based on the need to extract functionally viable cells for downstream single-cell omic analysis.

Incorporating automated tissue disaggregation devices into immune monitoring tissue analysis, upstream of the IsoLight Automated Proteomics Hub has been demonstrated to improve the ability to analyze rare functional subsets of live cells, that would be undetectable with other methods. This unlocks further areas to expand on a number of omic studies already being done on IsoPlexis’ systems, in areas like cancer immunology, infectious disease and vaccines, and inflammation and neurology.

Видео Improving cell health for single-cell proteomic analysis and immune monitoring канала Labroots